Screening of small molecule inhibitors for PLK1 PBD and evaluation of antitumor activities

JIANG Yu-huan1 ZHANG Jing2 CHEN Yun-yu2 WANG Yan-hong1 SI Shu-yi2

(1.Heilongjiang University of Chinese Medicine, Harbin, China 150000)
(2.Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China 100050)

【Abstract】With the method of fluorescence polarization (FP), we screened small molecule inhibitors for PLK1 PBD to identify the lead compounds for antitumor drugs. FP led to the identification of a potent hit, F083-0063, whose inhibition rate was (99.7 ± 0.4)% at 10 μg·mL−1. The IC50 was calculated to be 1.9 ± 0.1 μmol·L−1 using Graphpad Prism 5. The effect of the compound on cells' multiplication was measured by MTT assay which showed that F083-0063 inhibited the proliferation of many tumor cell lines. Flow cytometry analysis indicated that the F083-0063 promoted cell apoptosis and induced cell G2/M arrest. Migration abilities of cells, evaluated using scratch test, increased significantly in the presence of F083-0063 with the migration rate as low as (37.6 ± 0.7)% at 20 μmol·L−1. Molecular linkage technique found F083-0063 had good affinity with PLK1 PBD. The results of Western blotting showed that the expression of cyclin-dependent proteins was increased after treatment with F083-0063. In summary, F083-0063 has an antitumor activity and is expected to be an antitumor lead compound targeting PLK1 PBD.With the method of fluorescence polarization(FP),we screened small molecule inhibitors for PLK1 PBD to identify the lead compounds for antitumor drugs.FP led to the identification of a potent hit,F083-0063,whose inhibition rate was(99.7±0.4)%at 10μg·m L-1.The IC50 was calculated to be 1.9±0.1μmol·L-1 using Graphpad Prism 5.The effect of the compound on cells'multiplication was measured by MTTassay which showed that F083-0063 inhibited the proliferation of many tumor cell lines.Flow cytometry analysis indicated that the F083-0063 promoted cell apoptosis and induced cell G2/M arrest.Migration abilities of cells,evaluated using scratch test,increased significantly in the presence of F083-0063 with the migration rate as low as(37.6±0.7)%at 20μmol·L-1.Molecular linkage technique found F083-0063 had good affinity with PLK1 PBD.The results of Western blotting showed that the expression of cyclin-dependent proteins was increased after treatment with F083-0063.In summary,F083-0063 has an antitumor activity and is expected to be an antitumor lead compound targeting PLK1 PBD.

【Keywords】 antitumor drug; fluorescence polarization method; PLK1 PBD inhibitor; serine/threonine protein kinase; polo-like kinase inhibitor;

【DOI】

【Funds】 National Natural Science Foundation of China (Grant No.: 81370087)

Download this article

    References

    [1]Sunkel CE, Glover DM. Polo, a mitotic mutant of Drosophila displaying abnormal spindle poles[J]. J Cell Sic, 1988, 89: 25–38.

    [2]Li B, Ouyang B, Pan H, et al. Prk, a cytokine-inducible human protein serine/threonine kinase whose expression appears to be down regulated in lung carcinomas[J]. J Biol Chem, 1996, 271: 19402–19408.

    [3]Jang YJ, Ma S, Terada Y, et al. Phosphorylation of threonine210 and the role of serine 137 in the regulation of mammalian polo-like kinase[J]. J Biol Chem, 2002, 277: 44115–44120.

    [4]Zhang L, Cao YH, Lu S, et al. Targeting the substrate binding domain of polo-like kinase 1:advances in the study of PBD1inhibitors[J]. Acta Pharm Sin, 2013, 48: 315–324 (in Chinese).

    [5]Craig SN, Wyatt MD, Mc Innes C. Current assessment of polo-like kinase as anti-tumor drug targets[J]. Expert Opin Drug Discov, 2014, 9: 773–789.

    [6]Han DP, Zhu QL, Cui JT, et al. Polo-like kinase 1 is overexpressed in colorectal cancer and participates in the migration and invasion of colorectal cells[J]. Med Sci Monit, 2012, 18: BR237–BR246.

    [7]Gorlick R, Kolb EA, Keir ST, et al. Initial testing (stage 1) of the polo-like kinase inhibitor volasertib (BI 6727), by the Pediatric Preclinical Testing Program[J]. Pediatr Blood Cancer, 2014, 61: 158–164.

    [8]Lee KS, Idle JR. Pinning down the polo-box domain[J]. Chem Biol, 2008, 15: 415–416.

    [9]Strebhardt K. Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy[J]. Nat Rev Drug Discov, 2010, 9: 643–660.

    [10]Yun SM, Moulaei T, Lim D, et al. Structural and functional analyses of minimal phosphopeptides targeting the polo-box domain of polo-like kinase 1[J]. Nat Struct Mol Biol, 2009, 16: 876–882.

    [11]Liu F, Park JE, Qian WJ, et al. Serendipitous alkylation of a Plk1 ligand uncovers a new binding channel[J]. Nat Chem Biol, 2011, 7: 595–601.

    [12]Richter S, Neundorf I, Loebner K, et al. Phosphopeptides with improved cellular uptake properties as ligands for the polo-box domain of polo-like kinase 1[J]. Med Chem Lett, 2011, 21: 4686–4689.

    [13]ŚledźP, Stubbs CJ, Lang S, et al. From crystal packing to molecular recognition: prediction and discovery of a binding site on the surface of polo-like kinase 1[J]. Angew Chem Int Ed Engl, 2011, 50: 4003–4006.

    [14]ŚledźP, Lang S, Stubbs CJ, et al. High-throughput interrogation of ligand binding mode using a fluorescence-based assay[J]. Angew Chem Int Ed Engl, 2012, 51: 7680–7683.

    [15]Qian WJ, Park JE, Lim D, et al. Peptide-based inhibitors of Plk1 polo-box domain containing mono-anionic phosphothreonine esters and their pivaloyloxymethyl prodrugs[J]. Chem Biol, 2013, 20: 1255–1264.

    [16]Perrin F. Polarization of light of fluorescence, average life of molecules in the excited state[J]. J Phys Radium, 1926, 7: 390–401.

    [17]Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013[J]. CA Cancer J Clin, 2013, 63: 11–30.

    [18]Lane HA, Nigg EA. Antibody microinjection reveals an essential role for human polo-like kinase 1 Plk1 in the functional maturation of mitotic centrosomes[J]. J Cell Biol, 1996, 135: 1701–1713.

    [19]Jiang PD, Zhao YL, Shi W, et al. Cell growth inhibition, G2/M cell cycle arrest, and apoptosis induced by chloroquine in human breast cancer cell line Brap-37[J]. Cell Physiol Biochem, 2008, 22: 431–440.

    [20]Degenhardt Y, Lampkin T. Targeting polo-like kinase in cancer therapy[J]. Clin Cancer Res, 2010, 16: 384–389.

    [21]Lowery DM, Mohammad DH, Elia AE, et al. The polo-box domain: a molecular integrator of mitotic kinase cascades and polo-like function[J]. Cell Cycle, 2004, 3: 128–131.

    [22]Rudolph D, Steegmaier M, Hoffmann M, et al. BI 6727, a polo-like kinase inhibitor with improved pharmacokinetic profile and broad antitumour activity[J]. Clin Cancer Res, 2009, 15: 3094–3102.

    [23]Reindl W, Yuan J, Krämer A, et al. Inhibition of polo-like kinase 1 by blocking polo-box domain-dependent proteinprotein interactions[J]. Chem Biol, 2008, 15: 459–466.

    [24]Chen XN,Leanna L,Kwok PY.Fluorescence polarization in homogeneous nuleic acid analysis[J]. Genome Res, 1999, 9: 492–498.

    [25]Yin Z, Song Y, Rehse PH. Thymoquinone blocks p Ser/p Thr recognition by Plk1 polo-box domain as a phosphate mimic[J]. ACS Chem Biol, 2013, 8: 303–308.

This Article

ISSN:0513-4870

CN:11-2163/R

Vol 52, No. 03, Pages 409-415

March 2017

Downloads:2

Share
Article Outline

Abstract

  • Materials and methods
  • Results
  • Discussion
  • References